2016 – Page 9 – Policy & Medicine

What You Don’t Know About AMP Can Hurt You – Part 3 Can You Defend Your AMP?

HHS Issues Open Government Plan

Mylan Reaches Deal Over EpiPen Rebates

Getting to the Hub of the Matter: Analyzing the Compliance Needs for Hub Services

FDA Issues Draft Guidance on Real-World Data

The Debate Rages On: Should Clinical Trial Data Be Public?

Biosimilar User Fee Act (II) Performance Goals Letter Issued

FDA Announces Draft MDUFA Agreement

ACCME Releases Menu of New Criteria for Accreditation with Commendation

FDA Criticized for Moving Too Slowly